The DOI matches its Crossref record; 149 of the 149 references it cites were found in a registry or an index.
Anti-Drug Antibodies: Emerging Approaches to Predict, Reduce or Reverse Biotherapeutic Immunogenicity
Open accessAbstract
The development of anti-drug antibodies (ADAs) following administration of biotherapeutics to patients is a vexing problem that is attracting increasing attention from pharmaceutical and biotechnology companies. This serious clinical problem is also spawning creative research into novel approaches to predict, avoid, and in some cases even reverse such deleterious immune responses. CD4+ T cells are essential players in the development of most ADAs, while memory B-cell and long-lived plasma cells amplify and maintain these responses. This review summarizes methods to predict and experimentally identify T-cell and B-cell epitopes in therapeutic proteins, with a particular focus on blood coagulation factor VIII (FVIII), whose immunogenicity is clinically significant and is the subject of intensive current research. Methods to phenotype ADA responses in humans are described, including T-cell stimulation assays, and both established and novel approaches to determine the titers, epitopes and isotypes of the ADAs themselves. Although rational protein engineering can reduce the immunogenicity of many biotherapeutics, complementary, novel approaches to induce specific tolerance, especially during initial exposures, are expected to play significant roles in future efforts to reduce or reverse these unwanted immune responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Surface plasmon resonance (SPR)-based epitope mapping. (A). Representative superimposed sensorgrams showing single-cycle kinetics experiments in which rFVIII-C2 protein and rFVIII-C2 variants with a single surface-exposed side chain mutated to alanine were injected at increasing concentrations over a FVIII-specific MAb captured on a biosensor [97]. Residues were flagged as potential contributors to the epitope if the kd for the FVIII-C2 mutein was >2.0X the kd for the wild-type rFVIII-C2 protein. Alanine substitutions at residues E2228, L2252, S2254, H2315 and Q2316 met this criterion in this set of experiments with MAb 1B5. Separate SPR runs (not shown here) identified residues F2196, T2197, N2198, F2200, T2202, R2220, Q2222, N2225 and K2239 as also possibly contributing to the epitope recognized by this MAb. (B). Front and back views (rotated 180°) of the FVIII C2 domain crystal structure [100], with surfaces colored to indicate the 5 partially-overlapping B-cell epitopes recognized by 11 neutralizing MAbs. The MAbs and their cognate epitopes were designated Types A, AB, B, BC and C on the basis of competition ELISA experiments. These MAbs inhibit distinct binding interactions and functions of FVIII, e.g., binding to negatively charged phospholipid surfaces, von Willebrand factor, and other proteins comprising the ‘intrinsic tenase’ complex [88]. Type A: red; Type AB: orange; Type B: yellow; Type BC: green; Type C: blue.](https://figures.cochat.ai/paper-figures/b4e508965e1343178ea7e0a607aac94f/anti-drug-antibodies-emerging-approaches-to-predict-reduce-or-reverse-figure-1.jpg)
![Figure 2 “Saturation SPR” method to characterize polyclonal anti-FVIII anti-drug antibodies (ADAs) in patient plasma samples [114]. First a high-affinity MAb specific for the FVIII A1 domain is covalently immobilized on the biosensor surface, and FVIII protein is then injected and captured by this MAb (0–700 s, not shown in figure). A plasma sample (pre-treated with caprylic acid to minimize biosensor fouling) is injected next (black arrows) followed by sequential injections of anti-hu IgG1, IgG2, IgG3 and IgG4 MAbs (red arrows), all at saturating concentrations. The vertical displacements (in RUs) may be converted to total mass at the biosensor surface following each injection, which is then converted to the total bound antibody concentration assuming an average molecular weight of 150 kDa. (A–F): The red and blue sensorgram curves depict matched plasma samples pre-incubated with (red) and without (blue) saturating (1 µM) recombinant FVIII-C2 domain protein, which will compete with the polyclonal anti-FVIII-C2 antibodies in the plasma samples. Thus, these paired SPR experiments indicate the total anti-FVIII polyclonal antibody titer, the fractions of IgG1, IgG2, IgG3 and IgG4 in the samples, and the fraction of antibodies specific for the FVIII C2 domain. Panels A-E illustrate the diverse phenotypes of the anti-FVIII IgG response in patients with allo-or autoimmune anti-FVIII antibodies. Panel F is a control experiment in which a patient-derived IgG4 monoclonal antibody specific for the FVIII C2 domain is tested in the same assay. No patient samples contained FVIII-specific IgM or IgGA (not shown). (G) The biosensor assay format is shown schematically, with the FVIII crystal structure [116] in ribbon representation.](https://figures.cochat.ai/paper-figures/bddf0305c399452d842a643eeb770d03/anti-drug-antibodies-emerging-approaches-to-predict-reduce-or-reverse-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In many cases antibodies recognize the GalNAc moiety or otherwise non-neutralizing epitopes; in-vitro neutralization does not necessarily predict in-vivo functional loss.”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [54]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The siRNA delivery platform eliminates the chance of immune responses which affect protein-based medications because no anti-drug antibodies (ADAs) developed in trial participants [53, 54].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [54]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For example, immature dendritic cells (iDCs) are antigen presenting cells (APCs) that often present self-antigens without stimulating T cell responses, which may allow for tolerance of peptide sequences that could be harnessed in biotherapeutic treatments.143–145”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [144]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Consistent LDL-C suppression among antibody-positive individuals suggests limited clinical impact of the detected antibodies [53, 54].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [54]
Experimental — accuracy not yet measuredIn the citing paper
“modulating CD4+ T cell and B cell responses may assist in reducing ADAs.144”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [144]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Hot Spot of Binding Energy in a Hormone-Receptor Interface
Clackson, T., & Wells, J. A. (1995) · Science · doi:10.1126/science.7529940 · Cited by 1,983 · cited 1×
“In 1995, Clackson and Wells described “hot spots” within larger protein-protein binding interfaces that contribute most of the binding affinity [101].”
BackgroundCetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
Chung, C. H., Mirakhur, B., Chan, E., Le, Q.-T., Berlin, J., Morse, M., Murphy, B. A., Satinover, S. M., Hosen, J., Mauro, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074943 · Cited by 1,521
Sequence analysis of peptides bound to MHC class II molecules
Rudensky, A. Y., Preston-Hurlburt, P., Hong, S.-C., Barlow, A., & Janeway, C. A. (1991) · Nature · doi:10.1038/353622a0 · Cited by 1,075 · cited 1×
“A subset of these peptides may then be presented on an individual’s Major Histocompatability Complex (MHC), restricted to their HLA Class I and/or Class II alleles [25,26].”
BackgroundProPred: prediction of HLA-DR binding sites
Singh, H., & Raghava, G. P. S. (2001) · Bioinformatics · doi:10.1093/bioinformatics/17.12.1236 · Cited by 841
Fundamentals and Methods for T- and B-Cell Epitope Prediction
Sanchez-Trincado, J. L., Gomez-Perosanz, M., & Reche, P. A. (2017) · Journal of Immunology Research · doi:10.1155/2017/2680160 · Cited by 674 · cited 1×
“, peptide array or phage-display results, into epitope identification approaches greatly improves success rates, compared to ab initio methods based on amino acid sequence propensities to form beta turns, or machine-learning based algorithms [42].”
Hunt, D. F., Michel, H., Dickinson, T. A., Shabanowitz, J., Cox, A. L., Sakaguchi, K., Appella, E., Grey, H. M., & Sette, A. (1992) · Science · doi:10.1126/science.1319610 · Cited by 646
Lipid-reduction variability and antidrug-antibody formation with bococizumab
Ridker, P. M., Tardif, J.-C., Amarenco, P., Duggan, W., Glynn, R. J., Jukema, J. W., Kastelein, J. J. P., Kim, A. M., Koenig, W., Nissen, S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614062 · Cited by 369
Abshire, T., & Kenet, G. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.00759.x · Cited by 314
Structure of the C2 domain of human factor VIII at 1.5 Å resolution
Pratt, K. P., Shen, B. W., Takeshima, K., Davie, E. W., Fujikawa, K., & Stoddard, B. L. (1999) · Nature · doi:10.1038/46601 · Cited by 308
Self-citation
Cited by
Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions
Drag, S., Dotiwala, F., & Upadhyay, A. K. (2023) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.64.7.39 · Cited by 145
Jarantow, S. W., Pisors, E. D., & Chiu, M. L. (2023) · Current Protocols · doi:10.1002/cpz1.801 · Cited by 161
“Immunogenicity assessments such as anti-drug antibody assays (Adan et al. 2016) detect immune responses against a therapeutic, which can be immunogenic and/or neutralizing, and significantly affect PK/PD behavior (Pratt, 2018; Song et al., 2016).”
BackgroundImmunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics
Carter, P. J., & Quarmby, V. E. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01051-x · Cited by 122
“For example, a substantial proportion of patients with haemophilia A develop neutralizing ADAs — ‘inhibitors’ in the lexicon of haematolo-gists — when treated with replacement clotting factors 45 .”
Assessing developability early in the discovery process for novel biologics
Fernández‐Quintero, M. L., Ljungars, A., Waibl, F., Greiff, V., Andersen, J. T., Gjølberg, T. T., Jenkins, T. P., Voldborg, B. G. R., Grav, L. M., Kumar, S., et al. (2023) · mAbs · doi:10.1080/19420862.2023.2171248 · Cited by 108
eDiaPredict: An Ensemble-based Framework for Diabetes Prediction
Singh, A., Dhillon, A. P., Kumar, N., Hossain, M. S., Muhammad, G., & Kumar, M. (2021) · ACM Transactions on Multimedia Computing Communications and Applications · doi:10.1145/3415155 · Cited by 93
“The dataset is preprocessed for missing values, and further feature extraction is performed with the help of RFE [47].”
MethodMartin, K., Grimaldi, C. M., Grempler, R., Hansel, S. B., & Kumar, S. (2023) · mAbs · doi:10.1080/19420862.2023.2191301 · Cited by 82
“107,108 In addition to the type of the antibody, other factors such as molecular sequence features (e.g., presence or absence of T-and B-cell immune epitopes, stability/ aggregation of the molecule under physiological conditions), manufacturing processes, formulation, aggregates already present at…”
BackgroundKim, C., Yang, H., Kim, I. H., Kang, B., Kim, H., Kim, H., Lee, W. S., Jung, S., Lim, H. Y., Cheon, J., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.4733 · Cited by 59
Beyond Efficacy: Ensuring Safety in Peptide Therapeutics through Immunogenicity Assessment
Achilleos, K., Petrou, C. C., Nicolaidou, V., & Sarigiannis, Y. M. (2025) · Journal of Peptide Science · doi:10.1002/psc.70016 · Cited by 54
“This unfavourable immune response results in the production of ADAs, which can impact a biotherapeutic's pharmacokinetics (altering the drug's clearance rate), pharmacodynamics, effectiveness and even safety [23, 24].”
Radiolabelling small and biomolecules for tracking and monitoring
Edelmann, M. R. (2022) · RSC Advances · doi:10.1039/d2ra06236d · Cited by 56
Interleukin 23 and autoimmune diseases: current and possible future therapies
Abdo, A. I. K., & Tye, G. J. (2020) · Inflammation Research · doi:10.1007/s00011-020-01339-9 · Cited by 47
T-cell–engaging Therapy for Solid Tumors
de Miguel, M., Umaña, P., de Morais, A. L. G., Moreno, V., & Calvo, E. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2448 · Cited by 43
“First, antidrug antibodies (ADA) may appear after TCE infusion, mediated by CD4 T lymphocytes, memory B cells, and plasma cells (47, 48).”
BackgroundApproaches for the detection and analysis of antidrug antibodies to biopharmaceuticals: A review
Suh, K., Kyei, I., & Hage, D. S. (2022) · Journal of Separation Science · doi:10.1002/jssc.202200112 · Cited by 43
Mehta, P., & Manson, J. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00589 · Cited by 40
“Prediction of immunogenicity may allow mitigation and management strategies to be implemented to prevent or minimize the generation of ADAs (73).”
BackgroundInfluentialPlant Viruses and Bacteriophage-Based Reagents for Diagnosis and Therapy
Shukla, S., Hu, H., Cai, H., Chan, S. K., Boone, C. E., Beiss, V., Chariou, P. L., & Steinmetz, N. F. (2020) · Annual Review of Virology · doi:10.1146/annurev-virology-010720-052252 · Cited by 43
Kaneda, M., Kawasaki, R., Matsumoto, N., Abe, H., Tashiro, Y., Inokuchi, Y., Yasuno, H., Sasaki‐Noguchi, M., Soeda, T., Yoshimura, Y., et al. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15506 · Cited by 43
Lenders, M., & Brand, E. (2021) · Drugs · doi:10.1007/s40265-021-01621-y · Cited by 43
“Since high ADA affinities seem to be associated with increasing inhibitory capacities [69], while decreasing affinities might indicate the onset of tolerization [70], appropriate analyses will be of interest in future studies to identify FD patients at risk.”
BackgroundHarnessing the liver to induce antigen-specific immune tolerance
Gottwick, C., Carambia, A., & Herkel, J. (2022) · Seminars in Immunopathology · doi:10.1007/s00281-022-00942-8 · Cited by 42
Cohen, S., Myneni, S., Batt, A. R., Guerrero, J., Brumm, J., & Chung, S. (2021) · mAbs · doi:10.1080/19420862.2021.1898831 · Cited by 39
“ADAs can affect the pharmacokinetics, pharmacodynamics, efficacy, and even the safety of a biotherapeutic.(1) The incidence, magnitude, and duration of an ADA response depends on characteristics of both the patient and the biotherapeutic.”
BackgroundHarnessing the Complete Repertoire of Conventional Dendritic Cell Functions for Cancer Immunotherapy
Amon, L., Hatscher, L., Heger, L., Dudziak, D., & Lehmann, C. H. K. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12070663 · Cited by 40
Shores, L. S., Kelly, S. H., Hainline, K. M., Suwanpradid, J., MacLeod, A. S., & Collier, J. H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01855 · Cited by 38
“Although both approaches target a single epitope of the target cytokine, induced polyclonal antibody responses could have their affinity improved by repeated booster immunizations (16), can avoid any anti-antibody responses from foreign epitopes that vary by population (17), and provides a significantly longer half-li…”
BackgroundSensi, M., de Oliveira, R. F., Berto, M., Palmieri, M., Ruini, E., Livio, P. A., Conti, A., Pinti, M., Salvarani, C., Cossarizza, A., et al. (2023) · Advanced Materials · doi:10.1002/adma.202211352 · Cited by 31
Körber, I., Klein, O. D., Morhart, P., Faschingbauer, F., Grange, D. K., Clarke, A. J., Bodemer, C., Maitz, S. B., Huttner, K. M., Kirby, N., et al. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14301 · Cited by 32
“The administration of a recombinant protein to patients carries a risk of eliciting anti-drug antibodies that may reduce the clinical benefit in case of repeated application by affecting clearance, pharmacodynamics and pharmacokinetics (PK) of the drug or may even neutralize its therapeutic effects entirely.(15) If de…”
BackgroundLuo, Y. R., Chakraborty, I., Lázár‐Molnár, E., Wu, A. H. B., & Lynch, K. L. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa179 · Cited by 25
Engineering therapeutic antibodies for patient safety: tackling the immunogenicity problem
Ulitzka, M., Carrara, S. C., Grzeschik, J., Kornmann, H., Hock, B. M., & Kolmar, H. (2020) · Protein Engineering Design and Selection · doi:10.1093/protein/gzaa025 · Cited by 32
Role of Small Intestine and Gut Microbiome in Plant-Based Oral Tolerance for Hemophilia
Kumar, S. R. P., Wang, X., Avuthu, N., Bertolini, T. B., Terhorst, C., Guda, C., Daniell, H., & Herzog, R. W. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00844 · Cited by 29
The Novelty of mRNA Viral Vaccines and Potential Harms: A Scoping Review
Halma, M. T. J., Rose, J., Jenks, A., & Lawrie, T. A. (2023) · J — Multidisciplinary Scientific Journal · doi:10.3390/j6020017 · Cited by 26
Immunotherapies for the Treatment of Drug Addiction
Hossain, M. K., Davidson, M., Kypreos, E., Feehan, J., Muir, J. A., Nurgali, K., & Apostolopoulos, V. (2022) · Vaccines · doi:10.3390/vaccines10111778 · Cited by 27
Wang, J., White, J., Sansone, K. J., Spelman, L. J., Sinclair, R. D., Yang, X., Pan, W., & Wei, Z. (2023) · Clinical and Translational Science · doi:10.1111/cts.13656 · Cited by 25
“37 Few participants developed ADAs following exposure to rademikibart and incidence did not increase with dose.”
BackgroundLee, B. S., Lee, Y., Park, J., Jeong, B. S., Jo, M., Jung, S. T., & Yoo, T. H. (2019) · Journal of Biological Engineering · doi:10.1186/s13036-019-0188-x · Cited by 22
Näslund‐Koch, C., Zachariae, C. O. C., & Skov, L. (2020) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s227880 · Cited by 23
Could We Predict the Response of Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma?
Lee, C., Chan, S. L., & Chon, H. J. (2022) · Cancers · doi:10.3390/cancers14133213 · Cited by 24
Hypersensitivity and Immune-related Adverse Events in Biologic Therapy
Waldron, J. L., Schworer, S. A., & Kwan, M. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-021-08879-w · Cited by 26
“ADAs are induced after multiple tolerated exposures to the biologic agent [8, 9, 28].”
BackgroundHypersensitivity Reactions to Monoclonal Antibodies in Children
Mori, F., Saretta, F., Bianchi, A., Crisafulli, G., Caimmi, S. M. E., Liotti, L., Bottau, P., Franceschini, F., Paglialunga, C., Ricci, G., et al. (2020) · Medicina · doi:10.3390/medicina56050232 · Cited by 21
An Integrated Analysis of Dostarlimab Immunogenicity
Lu, S. M., Bowsher, R. R., Clancy, A., Rosen, A., Zhang, M., Yang, Y., Köeck, K., Gao, M., Potocka, E., Guo, W., et al. (2021) · The AAPS Journal · doi:10.1208/s12248-021-00624-7 · Cited by 18
Nakamura, S., Wada, M., Mizushima, T., Sugita, A., Tazuke, Y., Ohge, H., Udagawa, E., Suzuki, R. K., Yoon, M., Grimm, A. A., et al. (2022) · Surgery Today · doi:10.1007/s00595-022-02587-4 · Cited by 19
“Generally, anti-drug antibodies can reduce the efficacy of drugs as well as cause AEs in patients, resulting in such treatments not being a viable option for patients [33, 34].”
BackgroundWang, H., Hao, X., He, Y., & Fan, L. (2024) · PLoS ONE · doi:10.1371/journal.pone.0296737 · Cited by 28
“In-silico In-silico and immunoinformatic analysis-based methods are able to avoid these shortcomings to a large extent [14].”
BackgroundImmunogenicity of Protein Therapeutics: A Lymph Node Perspective
Fu, K., March, K., Alexaki, A., Fabozzi, G., Moysi, E., & Petrovas, C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00791 · Cited by 18
“The cascade begins with (1) dendritic cells that present the”
BackgroundImmunogenicity of monoclonal antibody: Causes, consequences, and control strategies
Asmani, A. Z. A., Zainuddin, A. F. F., Murad, N. A. A., Darwis, N. H. M., Suhaimi, N. S., Zaini, E., Taher, M., Susanti, D., & Khotib, J. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155627 · Cited by 22
Wenzel, T. J., Kwong, E. H., Bajwa, E., & Klegeris, A. (2020) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527319666200702143719 · Cited by 16
Pratt, K. P., Arruda, V. R., & Lacroix‐Desmazes, S. (2020) · Haemophilia · doi:10.1111/hae.14077 · Cited by 21
Self-citationKamala, O., Malik, T. H., Hallam, T. M., Cox, T. E., Yang, Y., Vyas, F., Luli, S., Connelly, C., Gibson, B. G., Smith‐Jackson, K., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.752916 · Cited by 17
Antibody-based therapy: An alternative for antimicrobial treatment in the post-antibiotic era
Luo, L., Li, Q., Chen, X., Li, C., Pan, Y., Sun, H., Yu, X., Wen, K., Shen, J., & Wang, Z. (2024) · Microbiological Research · doi:10.1016/j.micres.2024.127974 · Cited by 14
In Vitro Immunogenicity Prediction: Bridging between Innate and Adaptive Immunity
Cohen, S., & Chung, S. (2021) · Bioanalysis · doi:10.4155/bio-2021-0077 · Cited by 15
Medical Management of Hypophosphatasia: Review of Data on Asfotase Alfa
Dahir, K. M., & Dunbar, N. (2025) · Current Osteoporosis Reports · doi:10.1007/s11914-025-00906-5 · Cited by 11
“It is well established, however, that nAbs can negate the clinical benefit of biologics, while non-neutralizing antibodies can also reduce efficacy, for example by affecting clearance, pharmacodynamics and pharmacokinetics [48].”
Current status of the immunogenicity of enzyme replacement therapy in fabry disease
Gómez-Cerezo, J. F., Fernández-Martín, J., Barba-Romero, M. Á., Sánchez‐Martínez, R., Ameijeiras, Á. H., Camprodón-Gómez, M., Ortolano, S., & Rodriguez, M. L. (2025) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-025-03705-4 · Cited by 11
“Given that high affinity for ADAs is seemingly associated to increasing inhibitory abilities [56], whereas a decreasing affinity may point at the start of tolerance induction [57], performing the appropriate analyses is crucial for identify FD patients at risk [27].”
Dent, M. W., Mayer, K. L., Garcia, N. V., Guo, H., Kajiura, H., Fujiyama, K., & Matoba, N. (2022) · Plant Biotechnology Journal · doi:10.1111/pbi.13902 · Cited by 14
“As a foreign protein, AvFc administration in mice would result in the generation of antidrug antibodies (ADAs), which could compromise the safety and efficacy of the drug (Pratt, 2018).”
Sugiyama, N., Terry, F. E., Gutiérrez, A. H., Hirano, T., Hoshi, M., Mizuno, Y., Martin, W. D., Yasunaga, S., Niiro, H., Fujio, K., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1377911 · Cited by 11
Hosseingholi, E. Z., Neghabi, N., Molavi, G., Hayat, S. M. G., & Shahriarpour, H. (2020) · IUBMB Life · doi:10.1002/iub.2237 · Cited by 11
“The administration of therapeutic protein products to patientsmay be associated with eliciting antidrug antibodies.(65) There are many experimental and protein engineering methods for assessment of the immunological properties of biological drugs and reducing the immunogenicity of biotherapeutics.”
BackgroundHalf-life extension of therapeutics: Applications and mechanisms
Pathivada, K., & Glassman, P. M. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103724 · Cited by 9
Joshi, R., Sharma, S., Kapoor, D. U., Prajapati, B. G., Huanbutta, K., & Sriamornsak, P. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00774 · Cited by 11
Pharmacokinetics and Toxicity Considerations for Antibody–drug Conjugates: An Overview
Hejmady, S., Pradhan, R., Kumari, S., Pandey, M., Dubey, S. K., & Taliyan, R. (2023) · Bioanalysis · doi:10.4155/bio-2023-0104 · Cited by 9
Adapting protein sequences for optimized therapeutic efficacy
Dellas, N., Liu, J., Botham, R. C., & Huisman, G. W. (2021) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2021.03.005 · Cited by 10
Biopredictive tools for the development of injectable drug products
Nova, M. V., Gan, K., & Wacker, M. G. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2081682 · Cited by 10
“Such a change in drug elimination is difficult to mimic in-vitro, and it will potentially be integrated in-silico [54,55].”
BackgroundAssessment and impact of dose escalation on anti-drug antibodies in Fabry disease
Lenders, M., & Brand, E. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1024963 · Cited by 8
Halawa, M., Akantibila, M., Reid, B. E., & Carabetta, V. J. (2023) · Frontiers in Bacteriology · doi:10.3389/fbrio.2023.1304444 · Cited by 7
Discovery and Evaluation of TLR-Targeted Immune Agonists
Chernyak, N., Bhagwat, B., Naravula, S., Chen, Y., Solban, N., Zhang, F., Kofman, E., Raoufi, F., Dang, X., Bao, J., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00804 · Cited by 9
Lenders, M., Scharnetzki, D., Heidari, A., Iorio, D. D., Wegner, S. V., & Brand, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052680 · Cited by 8
Coxon, C. H., Yu, X., Beavis, J., Saez, L. D., Riches‐Duit, A., Ball, C., Diamond, S. L., & Raut, S. (2021) · British Journal of Haematology · doi:10.1111/bjh.17227 · Cited by 8
Bootwala, A., An, H. H., Franklin, M. W., Manning, B. J., Xu, L. Y., Panchal, S., Garlick, J. D., Baral, R., Hudson, M. E., Grigoryan, G., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1016179 · Cited by 7
Papenfuss, T. L., Himmel, L. E., Kuper, C. F., Mohanan, S., Harleman, J. H., & Elmore, S. A. (2023) · Toxicologic Pathology · doi:10.1177/01926233231190382 · Cited by 7
“41-44 The most clinically relevant immune effects of ADAs are mediated via the formation of biotherapeutic ADA immune complexes and their deposition in and around blood vessels in many organs.”
BackgroundSharma, A., & Singh, T. G. (2025) · Brain Research · doi:10.1016/j.brainres.2025.150047 · Cited by 8
Coelewij, L., Adriani, M., Dönnes, P., Waddington, K. E., Ciurtin, C., Havrdová, E., Farrell, R. A., Nytrová, P., Pineda‐Torra, I., & Jury, E. C. (2024) · Clinical Immunology · doi:10.1016/j.clim.2024.110339 · Cited by 6
Eltahir, M., Laurén, I., Lord, M., Chourlia, A., Dahllund, L., Olsson, A., Saleh, A., Ytterberg, A. J., Lindqvist, A., Andersson, O., et al. (2022) · Advanced Therapeutics · doi:10.1002/adtp.202200008 · Cited by 8
Satyam, S. M., El-Tanani, M., Patni, M. A., Rehman, A., Irshad, S. M., Raheem, R., Junais, E., John, A. A., Rassal, R. Y., Kumari, R., et al. (2026) · BMC Cardiovascular Disorders · doi:10.1186/s12872-026-05515-3 · Cited by 5
“The siRNA delivery platform eliminates the chance of immune responses which affect protein-based medications because no anti-drug antibodies (ADAs) developed in trial participants [53, 54].”
Leisegang, R. F., Baumann, H. E. S., Lennon-Chrimes, S., Ito, H., Miya, K., Genin, J., & Plan, E. L. (2024) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13230 · Cited by 5
Advances in immunotoxin engineering: precision therapeutic strategies in modern oncology
Oghalaie, A., Hosseini, M. E., Hosseininejad-Chafi, M., Eftekhari, Z., Behdani, M., & Kazemi‐Lomedasht, F. (2024) · Medical Oncology · doi:10.1007/s12032-024-02478-3 · Cited by 4
“Using immunosuppressive drugs like Bortezomib, Pentosta-tin, and Cyclophosphamide can significantly reduce the formation of anti-drug antibodies (ADAs) [93] (Fig.”
Wawrzyniak, M., Morsy, Y., Mladenov, R., Tontodonati, G., Turgay, Y., Herwig, S., Back, J., Mally, M., Faridmoayer, A., & Scharl, M. M. (2021) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjab038 · Cited by 4
Das, G., Ptáček, J., Campbell, J., Li, X., Havlínová, B., Noonepalle, S. K. R., Villagra, A., Bařinka, C., & Nováková, Z. (2025) · PLoS ONE · doi:10.1371/journal.pone.0307353 · Cited by 3
“…of the 5D3/CP33 engager to mediate targeted elimination of PSMA-positive cancer cells at particularly low concentrations would be beneficial in vivo , where lower dosage can minimize adverse immunogenic effects such as the anti-drug antibody (ADA) response or the cytokine release syndrome [80,81].”
Abdo, A. I. K., Nordin, F., & Tye, G. J. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112371 · Cited by 2
de Santaella, J. F., Koch, N. G., Widmer, L., & Nash, M. A. (2025) · ACS Chemical Biology · doi:10.1021/acschembio.4c00692 · Cited by 2
Brinth, A. R., Svenson, K., Mosyak, L., Cunningham, O., Hickling, T. P., & Lambert, M. A. (2022) · Scientific Reports · doi:10.1038/s41598-022-12838-6 · Cited by 2
Precision medicine in autoimmune disease
Deane, K. D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820239-5.00005-x · Cited by 1
Suttichet, T. B., Chamnanphon, M., Pongpanich, M., Chokyakorn, S., Kupatawintu, P., Srichomthong, C., Chetruengchai, W., Chuntakaruk, H., Rungrotmongkol, T., Chariyavilaskul, P., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-50211-3 · Cited by 1
“However, the immunogenic antibody activated by rHuEPO was related to T cell activation 23,24 .”
BackgroundAmin, K., Li, J., Lyu, B., Wang, S., Fu, H., Liu, B., & Yu, H. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125983 · Cited by 1
Ouchi, K., Inoue, J., Ninomiya, M., Tsuruoka, M., Sato, K., Doi, K., Watanabe, K., Sasazaki, T., & Masamune, A. (2026) · Hepatology Research · doi:10.1111/hepr.70162 · Cited by 1
Commonly setting biological standards in rare diseases
O’Connor, D. J., Buckland, J., Almond, N. M., Boyle, J., Coxon, C. H., Gaki, Ε., Martín, J. E.-S., Mattiuzzo, G., Metcalfe, C. L., Page, M., et al. (2019) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2019.1652598 · Cited by 1
MuTaTo©—A Novel Concept for Curing Cancer
Morad, I., & Itzhaki, H. (2020) · Journal of Cancer Therapy · doi:10.4236/jct.2020.112006 · Cited by 1
“The fact that MuTaTo constructs are flexible with no rigid structure, and contain only small peptides, not only contribute to their ability to penetrate solid tumors, but also to escape immune response that can cause drug depletion comparing to other constructs with similar size, like antibodies [17].”
BackgroundEngineering Therapeutic Antibodies for Development
Kornmann, H., & Hock, B. M. (2020) · Learning materials in biosciences · doi:10.1007/978-3-030-54630-4_12 · Cited by 1
Methods to Evaluate the Effects of Synonymous Variants
Lin, B. C., Jankowska, K. I., Meyer, D., & Katneni, U. (2022) · Springer eBooks · doi:10.1007/978-3-031-05616-1_7 · Cited by 2
Dent, M. W., Mayer, K. L., Garcia, N. V., Guo, H., Kajiura, H., Fujiyama, K., & Matoba, N. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.31.494188 · Cited by 1
“Pretreatment with AvFc increases survival in the B16F10 flank tumor model As a foreign protein, AvFc administration in mice would result in the generation of anti-drug antibodies (ADAs), which in theory could compromise the safety and efficacy of the drug (Pratt, 2018).”
BackgroundGeorge, K. L. (2019) · D-Scholarship@Pitt (University of Pittsburgh)
Brinth, A. R., Svenson, K., Mosyak, L., Cunningham, O., Hickling, T. P., & LAMBERT, M. T. B. (2021) · Research Square · doi:10.21203/rs.3.rs-751879/v1
Xu, Z. (2020) · ScholarlyCommons (University of Pennsylvania)
結核菌の縦列反復配列多型(VNTR)解析に基づく分子疫学とその展望 : 大阪市の例
和田, 崇., & 長谷, 篤. (2010) · 結核
Mauro, V. P. (2022) · Springer eBooks · doi:10.1007/978-3-031-05616-1_10
Q-Griffithsin interactions and utility for the prevention and treatment of Mucosal infections.
Nabeta, H. W. (2021) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/3766 · Cited by 1
Immunogenicity and Immune-Related Adverse Drug Reactions
Mihalcik, L., Bussiere, J. L., Allamneni, K. P., Jawa, V., Lepherd, M., Mytych, D. T., Sirivelu, M. P., & Everds, N. E. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.00066-8
Petrotchenko, E. V., Hahn, A., & Borchers, C. H. (2025) · Antibodies · doi:10.3390/antib14030064
“Knowledge of the epitopes can be helpful for new approaches to predict, avoid, or even reverse such deleterious immune responses [3].”
Modulation of T Cell Regulation by Interleukin-2 Agonists: Mechanisms and Clinical Implications
Sonak, S. S., Ishwarkar, S., Nimbarte, C., & Nimbarte, V. D. (2025) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2025059823
Nabhan, M. (2019) · theses.fr (ABES) · doi:10.70675/2e687124z7c14z4b40z9e34zdc961f83e886 · Cited by 1
Development of a flow cytometry method to measure antidrug antibodies against CAR T cells
Day, G., Sánchez-Martín, F. J., Seavers, L., Cadwallader, K. A., & Morgado-García, S. (2026) · ImmunoHorizons · doi:10.1093/immhor/vlag011
“This includes ADAs altering efficacy by affecting clearance, pharmacodynamics, and pharmacokinetics, or even completely neutralizing the drug 36 to more severe infusion reactions caused by hypersensitivity.”
Issues and Problems for the Biopharmaceutical Industry
Sahoo, S. P., & Bhujabal, S. (2026) · doi:10.1002/9781394440559.ch6
Florescu, A., Vintilă, T. C., Vasiliu, I., Bădulescu, O. V., Ignat, A., Bararu‐Bojan, I., Lupu, V. V., Simionescu, B., Grosu, C., Iațentiuc, A., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27156921
“Clinical efficacy does not appear to be systematically affected by antibody positivity, and biochemical and radiographic improvements have been observed across pediatric cohorts irrespective of serologic status during the first year of therapy [90].”
Targeting angiogenesis: advances in the design and engineered applications of nanobodies
Liu, Y., Li, Z., Ma, Y., & Liu, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1912560
“Chronic dosing regimens required for solid tumors or autoimmune disorders increase the risk of anti-drug antibody (ADA) development, as evidenced by clinical data showing ADA incidences exceeding 30% in some nanobody programs (ALX-0061) (76, 77).”
Metadata
- Authors
- Pratt, K. P.
- Affiliations
- Uniformed Services University of the Health Sciences (US)
- Corresponding author
- Pratt, Kathleen P.
- ORCID
- Pratt, Kathleen P.
- Venue
- Antibodies
- Publisher
- MDPI AG
- Published
- 2018-05-31
- Volume
- 7
- Issue
- 2
- Pages
- 19
- ISSN
- 2073-4468 (ISSN-L)
- PMC
- PMC6698869
- OpenAlex
- W2806365218
- Cited by
- 96
- References
- 149
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 11 · 2023: 11 · 2022: 16 · 2021: 15 · 2020: 19 · 2019: 5 · 2018: 1
- FWCI
- 1.02
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Antibodies (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Heart, Lung, and Blood Institute (1R01 HL 130448)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Keywords
- anti-drug antibodies, CD4+ T cells, memory B cells, long-lived plasma cells, epitope prediction, rational protein design, immune tolerance induction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.